News
--(BUSINESS WIRE)--Upstream Bio, a clinical-stage biotech company advancing new therapies to treat inflammation, today announced the initiation of a Phase 1b multiple ascending dose study of UPB ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback